Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-Cell lymphoma: A randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)

Cancer

Volumn 115, Issue 19, 2009, Pages 4540-4546

  Ribrag, Vincent ^a   Gisselbrecht, Christian ^b   Haioun, Corinne ^c   Salles, Gilles ^d   Golfier, Jean Baptiste ^b   Ertault, Marjan ^b   Ferme, Christophe ^a   Briere, Josette ^b   Brice, Pauline ^b   Mounier, Nicolas ^e,f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f France EDHEC Risk Institute   (France)

Author keywords

B cell lymphoma; Bortezomid; Chemotherapy; Phase 2 trial; Rituximab

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEART DISEASE; HUMAN; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHIC PAIN; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PREDNISONE; PYRAZINES; VINCRISTINE;

EID: 70349300630     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24518     Document Type: Article

References (13)

1. Coiffier B, Lepage E, Briere J, et al. CHOP plus rituximab with CHOP chemotherapy in elderly patients with diffuse large B-Cell lymphoma. A Groupe d'Etude des Lymphomes de l'Adulte study. N Engl J Med. 2002;346:235-242.
2. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423. (Pubitemid 40223656)
3. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
4. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377-2380. (Pubitemid 36302084)
5. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667-675. (Pubitemid 46224166)
6. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676-684. (Pubitemid 46237441)
7. Benichou J, Bellissant E, Chastang C. Analysis of phase II clinical trials in haematology and oncology: comparison of the triangular test to the usual methods. Stat Med. 1991;10:989-990.
8. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non- Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253. (Pubitemid 29162950)
9. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867-4874. (Pubitemid 46655613)
10. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group Trial IND. 150. Ann Oncol. 2007;18:116-121.
11. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105:3058-3065. (Pubitemid 40504321)
12. Leonard JP, Furman RR, Cheung YK, et al. CHOP-R + bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL) [abstract]. J Clin Oncol. 2007;25:18S. Abstract 8031.
13. Kahl B, Chang J, Eickhoff J, et al. VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin Oncology Network [abstract]. Blood. 2008;112:11S. Abstract 265.